Lacosamide is generally safe and well tolerated when used to treat patients with painful diabetic neuropathy, investigators announced here at the 60th Annual Meeting of the American Academy of Neurology (AAN). Lacosamide (LCM) is an anticonvulsant under investigation for its potential effect in decreasing diabetic neuropathic pain.

A recent study found that looking at proteins in urine might help doctors figure out who is more likely to develop the condition called diabetic nephropathy. Learn more...

Foot infections are common among diabetic patients and are a major cause of hospitalization and amputation. A multidisciplinary surgical and medical team is necessary to adequately treat severe diabetic foot infection.

Boston Scientific Corporation (NYSE: BSX) announced results from a pooled analysis of patients from its TAXUS IV and TAXUS V randomized clinical trials. The analysis compared the safety and efficacy of the TAXUS(R) Express(TM) Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients.

Charles Masison cured himself of Diabetes despite doctors telling him it was not possible to do so. In his 216 page book, "Winning The Fight Against Diabetes" Charles Masison describes how he was able to bring his Glucose reading down from a diabetic 178 to a non-diabetic 106.

A JDRF collaboration between Johns Hopkins researchers and Genentech has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.

UCB presented efficacy and safety results from pooled analyses of Phase II and III double-blind, randomized, placebo-controlled clinical trials investigating lacosamide for the treatment of diabetic neuropathic pain.

Two major eye diseases and leading causes of blindness -- age-related macular degeneration and diabetic retinopathy -- can be reversed or even prevented by drugs that activate a protein found in blood vessel cells, researchers at the University of Utah School of Medicine and several other institutions have announced in a new study.

MacroChem Corporation (OTC Bulletin Board: MACM) announced the presentation of a poster entitled "Topical versus Systemic Antimicrobial Therapy for Treating Infected Diabetic Foot Ulcers: A Randomized, Controlled, Double-Blinded, Multicenter Trial of Pexiganan Cream.

As part of ArthroCare Sports Medicine's recent entry into the Foot and Ankle arena, ArthroCare(R) Corp. (Nasdaq: ARTC) announced today that it has launched early stage clinical and pre-clinical research work for treating diabetic foot ulcers and is encouraged by preliminary results reported by physicians.

Researchers at the John A. Moran Eye Center at the University of Utah and collaborative institutions have identified a gene called erythropoietin that contributes to increased risk of severe diabetic eye and kidney diseases, called retinopathy and nephropathy.

Novagali Pharma, an emerging ophthalmic pharmaceutical company announced that it has successfully injected the first patient in a Phase I clinical trial using CORTIJECT(R), an ophthalmic injectable emulsion based on EYEJECT(R) technology platform containing a corticosteroid prodrug for the treatment of Diabetic Macular Edema (DME).

Kinetic Concepts, Inc. (NYSE:KCI) announced the final efficacy results of a randomized controlled clinical trial (RCT) on the clinical efficacy of KCI's V.A.C.(R) System negative pressure wound therapy (NPWT) compared to advanced moist wound therapy (AMWT) to treat diabetic patients with foot ulcers. The study, which showed that V.A.C.

Oramed Pharmaceuticals Inc. has been granted approval by the Institutional Review Board (IRB) committee of Hadassah Medical Center in Jerusalem to conduct a Phase 2A study of its oral insulin on diabetic volunteers. This Phase 2A study is designed to evaluate the safety and efficacy of Oramed's oral insulin capsule on Type II diabetic volunteers.

Associated Foot & Ankle Specialists announced it is recruiting patients with foot ulcers due to diabetes to participate in the MATRIX clinical trial. The trial will study the effects of a new product, Excellarate, for the potential treatment of patients with non-healing diabetic foot ulcers. Excellarate is an investigational product designed to stimulate the process of wound healing.